5-Aza-2′-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 278-285

  Cui, Min ^a   Wen, Zeqing ^a   Chen, Ji ^a   Yang, Zhongli ^a   Zhang, Hualing ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

5 Aza 2 deoxycytidine; Apoptosis; DNA methyltransferase 3B; DNA mismatch repair; Human; MLH1 protein

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; PROTEIN MLH1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG MECHANISM; ENDOMETRIUM CANCER; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; CELL SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA REPAIR; DNA REPAIR ENZYMES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NUCLEAR PROTEINS; UP-REGULATION;

EID: 77956931315     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9204-1     Document Type: Article

References (24)

1. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16:6-21. doi:10.1101/gad.947102. (Pubitemid 34049633)
2. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005;74:481-514. doi:10.1146/annurev.biochem.74.010904.153721. (Pubitemid 40995515)
3. Leonhardt H, Page AW, Weier HU, Bestor TH. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell. 1992;71:865-73. doi:10.1016/0092-8674(92)90561-P.
4. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247-57. doi:10.1016/S0092-8674(00)81656-6. (Pubitemid 29519904)
5. Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597-610. doi:10.1038/nrg1655. (Pubitemid 41044297)
6. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science.2003;300:455. doi:10.1126/science.1083557. (Pubitemid 36444319)
7. Jones PA, Baylin SB. The fundamental role of epigenetic eventsin cancer. Nat Rev Genet. 2002;3:415-28. doi:10.1038/nrg962.
8. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004;444:213-23. doi:10.1007/s00428-003-0947-3. (Pubitemid 38446432)
9. Kanaya T, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene. 2003;22:2352-60. doi:10.1038/sj.onc.1206365. (Pubitemid 36566790)
10. Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents. 2003;3:187-99. doi:10.2174/1568011033482440. (Pubitemid 36512029)
11. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001;134:573-86.
12. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483-95. doi:10.1038/sj.onc.1205699. (Pubitemid 34983483)
13. Petti MC, et al. Pilot study of 5-aza-2-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia. 1993;Suppl 1:36-41.
14. Kitagawa Y, et al. Demethylating reagent 5-azacytidine inhibits teloemerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin Cancer Res. 2000;6:2868-75.
15. Greger V, Passarge E, Hopping W, Messmer E, Horsthemke B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet. 1989;83:155-8.doi:10.1007/BF00286709.
16. Baylin SB, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001;10:687-92. doi:10.1093/hmg/10.7.687.
17. Salvesen HB, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer. 2001;91:22-6. doi:10.1002/1097-0215(20010101)91:13.0. CO;2-S.
18. Aebi S, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996;56:3087-90. (Pubitemid 26199755)
19. Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S, Dahiya R.Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res. 2001;61:97-102.
20. Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of microsatellite instability in endometrial carcinoma.Cancer Res. 1999;59:462-6.
21. Bird AP. The relationship of DNA methylation to cancer. Cancer Surv. 1996;28:87-101.
22. Issa JP. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat Clin Pract Oncol. 2005;2:S24-9. doi:10.1038/ncponc0355. (Pubitemid 43135231)
23. Issa JP, H Kantarjian. Azacitidine. Nat Rev Drug Discov. 2005;Suppl:S6-S7. doi:10.1038/nrd1726. (Pubitemid 40674335)
24. Momparler RL. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin Hematol. 2005;42:S9-16. doi:10.1053/j.seminhematol.2005.05.002. (Pubitemid 40961867)